ライフサイエンスコーパス: lysostaphin

1 enzybiotic cocktail consisting of CHAPK and lysostaphin.

2 X-100-induced autolysis and also to lysis by lysostaphin.

3 determined by ELISA and by neutralization of lysostaphin.

4 not alter the observed therapeutic values of lysostaphin.

5 S. aureus strain for 72 h in the presence of lysostaphin.

6 A single intravitreous injection of lysostaphin (0.1%) sterilized all eyes of immunized and

7 a single intravitreous injection (0.1 mL) of lysostaphin (0.1%).

8 were treated either topically with drops of lysostaphin (0.3%) or with a single intravitreous inject

9 S. aureus can be rescued by the addition of lysostaphin, a bacterial endopeptidase active at neutral

10 coccus simulans bv. staphylolyticus secretes lysostaphin, a bacteriocin that cleaves pentaglycine cro

11 Staphylococcus simulans secretes lysostaphin, a bacteriolytic enzyme that cleaves staphyl

12 Staphylococcus simulans secretes lysostaphin, a bacteriolytic enzyme that specifically bi

13 stitutions enables secretion of Gln(125,232)-lysostaphin, a bioactive variant.

14 surface protein is removed by treatment with lysostaphin, a glycyl-glycine endopeptidase that separat

15 Structural studies of lysostaphin, a PG lytic enzyme (autolysin), have suggest

16 gp13 and homologous residues in the LytM and lysostaphin active sites facilitate hydrolysis of the pe

17 ral new therapeutic agents (e.g. daptomycin, lysostaphin and a Staphylococcus aureus vaccine) are in

18 endopeptidases such as Staphylococcus aureus lysostaphin and LytM, and to DD-endopeptidases involved

19 of cell walls by autolytic enzyme extracts, lysostaphin and mutanolysin.

20 The sensitivity to lysostaphin and vancomycin were compared for 34 MRSA and

21 thelial defects (ISP546) were susceptible to lysostaphin, and inhibition of lysostaphin when harvesti

22 Anti-lysostaphin antibody titers were determined by ELISA and

23 -infected eyes, despite the presence of anti-lysostaphin antibody.

24 netic engineering, transgenic cows secreting lysostaphin at concentrations ranging from 0.9 to 14 mic

25 SH3b domains from either lysostaphin (bacteriocin) or LysK (phage endolysin) resu

26 Lysostaphin bound to the cell wall envelopes of lyrA mut

27 Rabbits were immunized against lysostaphin by subcutaneous, intranasal, or topical rout

28 anchored proteins, but it can be detected in lysostaphin cell wall extracts.

29 glycan-targeting glycylglycine endopeptidase lysostaphin, compared to the wild type.

30 opeptide 12, its peptide derivative, and its lysostaphin degradation products by high pressure liquid

31 erformance liquid chromatography analysis of lysostaphin digests of peptidoglycan suggest an increase

32 Thus, the CWT domain of lysostaphin directs the bacteriocin to cross-linked pept

33 We have discovered that the LytM (lysostaphin)-domain containing factors of E. coli (EnvC,

34 estion with the glycyl-glycine endopeptidase lysostaphin followed by the pneumococcal N-acetylmuramyl

35 ity with the N-terminal region of the mature lysostaphin from Staphylococcus simulans and 50% identit

36 sin CHAPK and the staphylococcal bacteriocin lysostaphin have been co-administered in a thermally tri

37 l pattern of beta-sheets are conserved among lysostaphin homologs (such as LytM of Staphylococcus aur

38 as little as 3 micrograms/ml [corrected] of lysostaphin in milk.

39 gene directed the secretion of Gln(125,232)-lysostaphin into milk, exhibit substantial resistance to

40 terminal cell wall-targeting domain (CWT) of lysostaphin is required for selective binding of this ba

41 Lysostaphin is very effective in treating keratitis medi

42 The protein, lysostaphin, is a peptidoglycan hydrolase normally produ

43 ALE-1, a homologue of lysostaphin, is a peptidoglycan hydrolase that specifica

44 mapped to envC (yibP), proposed to encode a lysostaphin-like, metallo-endopeptidase that is exported

45 tudy of S. aureus mutants with resistance to lysostaphin-mediated killing has revealed biosynthetic p

46 A lysostaphin molecule lacking the C-terminal targeting si

47 9 or 10 to 15 hours postinfection with 0.28% lysostaphin or 5.0% vancomycin.

48 zed from the peptidoglycan by treatment with lysostaphin or phi11 hydrolase and identified COOH-termi

49 periments were performed to demonstrate that lysostaphin penetrated the cornea to kill bacteria in vi

50 wall of S.aureus consisted of 92 C-terminal lysostaphin residues.

51 son insertion in SAV2335, herein named lyrA (lysostaphin resistance A), did not cause gross alteratio

52 Other lyr mutants with intermediate lysostaphin resistance carried bursa aurealis insertions

53 Lysostaphin resistance of lyrA mutants is attributable t

54 ted protease domain, caused a high degree of lysostaphin resistance, similar to the case for a previo

55 aureus strain Newman transposon mutants for lysostaphin resistance.

56 daSa2 endopeptidase domain by either LysK or lysostaphin SH3b domain differed by no more than a facto

57 normal and immunized rabbits with keratitis, lysostaphin significantly reduced the log CFU to less th

58 to staphylococci, whereas murein monomers or lysostaphin-solubilized cell wall fragments did not.

59 to two surface proteins (138 and 127 kDa) of lysostaphin-solubilized S. aureus.

60 ith early therapy (4 -9 hours postinfection) lysostaphin sterilized all MRSA 301-infected corneas, wh

61 ncentrations were at least 19-fold lower for lysostaphin than for vancomycin.

62 tensively diminished sensitivity to lysis by lysostaphin, the ability to form a biofilm, and a total

63 cts were observed with the administration of lysostaphin to either normal or immunized rabbit eyes.

64 reactions were produced by administration of lysostaphin to immunized rabbits.

65 presents a new selectivity method involving lysostaphin together with a CMOS-compatible impedance se

66 etrated the cornea to kill bacteria in vivo; lysostaphin-treated eyes were found to recover from infe

67 ours postinfection) the residual bacteria in lysostaphin-treated eyes were significantly less numerou

68 Lysostaphin treatment of immunized rabbits was effective

69 usceptible to lysostaphin, and inhibition of lysostaphin when harvesting corneas did not alter the ob

70 e M1 muramidase and decreased sensitivity to lysostaphin, which is a reversal of the susceptibility p